Centogene extends strategic partnership with takeda to continue providing access to genetic testing for patients with lysosomal storage disorders

Cambridge, mass. and rostock, germany and berlin, april 11, 2023 (globe newswire) -- centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has extended its partnership with takeda (tse: 4502/nyse: tak) to diagnose patients with lysosomal storage disorders (lsds).
CNTG Ratings Summary
CNTG Quant Ranking